While many Rare Inborn Errors of Metabolism are treatable conditions their optimal diagnosis and treatment is a challenge for nations with low resources. Moreover, the population prevalence of these conditions is largely unknown. The availability of large genomic datasets brings the opportunity to estimate population carrier frequency of autosomal recessive IEMs. This would help to generate diseases burden statistics for better allocation of resources. In the current work we estimated the gene specific combined minor allele frequency of pathogenic variants from the gnomAD dataset for 235 genes associated with IEM phenotypes in OMIM. As per our estimation almost one third of the Global population is carrier for a pathogenic variant responsible for rare autosomal recessive inborn error of metabolism with the highest carrier frequency in the Ashkenazi Jews. Globally per thousand live births approximately five children are born with an ARIEM. European Finnish have the highest burden of nine out of 10,000 live births. With 25 million live births per year India is expected to have at least 8,025 newborns with an ARIEM. Since many of these diseases are treatable early newborn screening holds the key to ensure optimal management of these children.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

gnomAD database

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors